These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16886519)

  • 41. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
    Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
    Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rivastigmine against dementia in Parkinson disease?].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2007 Nov; 127(22):2973; author reply 2973-4. PubMed ID: 18026256
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of rivastigmine on cognitive function in patients with traumatic brain injury.
    Silver JM; Koumaras B; Chen M; Mirski D; Potkin SG; Reyes P; Warden D; Harvey PD; Arciniegas D; Katz DI; Gunay I
    Neurology; 2006 Sep; 67(5):748-55. PubMed ID: 16966534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
    Matsui H; Udaka F; Tamura A; Oda M; Kubori T; Nishinaka K; Kameyama M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):36-40. PubMed ID: 16449759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hallucinations treated with rivastigmine in Creutzfeldt-Jakob disease.
    Chapuis C; Casez O; Lagrange E; Bedouch P; Besson G
    Fundam Clin Pharmacol; 2012 Apr; 26(2):212-4. PubMed ID: 21631588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rivastigmine for dementia associated with Parkinson's disease.
    Morgan J; Sethi KD
    Curr Neurol Neurosci Rep; 2005 Jul; 5(4):263-5. PubMed ID: 15987609
    [No Abstract]   [Full Text] [Related]  

  • 49. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The malignant course of "benign hallucinations" in Parkinson disease.
    Goetz CG; Fan W; Leurgans S; Bernard B; Stebbins GT
    Arch Neurol; 2006 May; 63(5):713-6. PubMed ID: 16682540
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
    Dautzenberg PL; Wouters CJ; Oudejans I; Samson MM
    Int J Geriatr Psychiatry; 2003 Jun; 18(6):555-6. PubMed ID: 12789683
    [No Abstract]   [Full Text] [Related]  

  • 52. Tactile hallucinations in Parkinson's disease.
    Fénelon G; Thobois S; Bonnet AM; Broussolle E; Tison F
    J Neurol; 2002 Dec; 249(12):1699-703. PubMed ID: 12529792
    [TBL] [Abstract][Full Text] [Related]  

  • 53. When and how should treatment be started in Parkinson disease?
    Lang AE
    Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Parkinson's disease: diagnosis and treatment.
    Rao SS; Hofmann LA; Shakil A
    Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine.
    Luykx HJ; Dorresteijn LD; Haffmans PM; Bonebakker A; Kerkmeer M; Hendriks VM
    Alcohol Alcohol; 2008; 43(1):70-2. PubMed ID: 17984137
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.
    Hely MA; Reid WG; Adena MA; Halliday GM; Morris JG
    Mov Disord; 2008 Apr; 23(6):837-44. PubMed ID: 18307261
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations.
    Whitehead DL; Davies AD; Playfer JR; Turnbull CJ
    Mov Disord; 2008 Jun; 23(8):1137-45. PubMed ID: 18442142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.